Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
36 Items
Title  Creator  Group name  Publishing year 
[Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey] Quesada et al. EquipePC 2023-04
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer Vendrell et al. EquipeCTCS 2023-09-16
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations Quesada et al. EquipePC 2022-02-23
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives Quesada et al. EquipePC 2022-02-21
ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets Cabello-Aguilar et al. EquipePC 2022-12-13
Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota Vendrell et al. EquipePC 2022-01-25
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families Imbert-Bouteille et al. EquipePC 2021-07-20
Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer Bellanger et al. EquipePC 2021
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome Vendrell et al. EquipePC 2021-11
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM Belthier et al. EquipeMY 2021-10-02
Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT Harmand and Solassol EquipePC 2020-10-16
TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma Blateau et al. EquipePC Aug 09, 2020
Proximal Protein Interaction Landscape of RAS Paralogs Béganton et al. EquipePC 2020-11-11
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer Fabbro et al. EquipeCTCS 2020-08-05
Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment Vendrell et al. EquipePC 2020
[New approaches for protein-protein interaction study] Béganton et al. EquipePC Mar 2019
Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs Vendrell et al. EquipeMY 2019-07-15
The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex Kassouf et al. EquipePC Dec 07, 2019
Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity Lacombe et al. EquipePC Aug 09, 2019
Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations Alegre et al. EquipePC Jun 01, 2019
Protein interactions study through proximity-labeling Béganton et al. PlateformePP2I Aug 2019
MIAmS: microsatellite instability detection on NGS amplicons data Escudié et al. EquipePC Oct 24, 2019
FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer Mangé et al. PlateformePP2I 2019
Dzip1 and Fam92 form a ciliary transition zone complex with cell type specific roles in Drosophila Lapart et al. PlateformePP2I 12 10, 2019
Alu element insertion in the MLH1 exon 6 coding sequence as a mutation predisposing to Lynch syndrome Solassol et al. EquipePC Feb 28, 2019
12>>>
36 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés